Inogen, Inc

As of June 30, 2026, Inogen, Inc carries a market capitalization of 172.41M, placing it among publicly traded companies globally. Its enterprise value stands at 82.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Inogen, Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Inogen, Inc has 26.73M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.49, and the price-to-book ratio stands at 0.99.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 82.67M versus a market cap of 172.41M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Inogen, Inc maintains a current ratio of 2.74, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Inogen, Inc posted a negative return on equity (ROE) of -13.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.23, reflecting losses generated across the asset base. The company generates approximately 468,501.16 in revenue per employee across its workforce of 756.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.43 indicates how many times Inogen, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Inogen, Inc recorded an income tax benefit of -710,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -25.30M and -24.59M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Inogen, Inc's stock has declined approximately 20.45% over the past 52 weeks. The 50-day moving average sits at 5.66, while the 200-day moving average is 6.21.

Over the twelve months ended June 30, 2026, Inogen, Inc generated 354.30M in revenue and converted that into -24.59M in net income, yielding earnings per share of -0.91. EBITDA reached -11.00M, while operating income came in at -30.85M.

As of June 30, 2026, Inogen, Inc holds 105.54M in cash and equivalents against 15.79M in total debt, resulting in a net debt position of -87.28M. Total book value stands at 174.86M, with working capital of 123.27M providing operational flexibility.

Inogen, Inc produced -2.51M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.17M in capital expenditures, free cash flow totaled -9.69M - equivalent to -0.36 per share.

Over the twelve months ended June 30, 2026, Inogen, Inc posted a gross margin of 44.51, reflecting its pricing power and cost economics. The operating margin of -8.71 and net profit margin of -6.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Inogen, Inc shareholders.

As of June 30, 2026, Inogen, Inc has an Altman Z-Score of 1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.